Gorana Tomasic

14.8k total citations · 3 hit papers
63 papers, 6.0k citations indexed

About

Gorana Tomasic is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Gorana Tomasic has authored 63 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 18 papers in Cancer Research and 15 papers in Molecular Biology. Recurrent topics in Gorana Tomasic's work include Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (12 papers) and Melanoma and MAPK Pathways (9 papers). Gorana Tomasic is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (12 papers) and Melanoma and MAPK Pathways (9 papers). Gorana Tomasic collaborates with scholars based in France, Italy and United States. Gorana Tomasic's co-authors include Valérie Boige, Michel Ducreux, Jean‐Baptiste Bachet, Pierre Laurent‐Puig, Astrid Lièvre, Jean‐François Emile, Delphine Le Corre, Philippe Rougier, Bruno Landi and Frédérique Penault‐Llorca and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Cancer.

In The Last Decade

Gorana Tomasic

60 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 1.7k citations Astrid Lièvre, Jean‐Baptiste Bachet et al. Cancer Research profile →
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 1.1k citations Astrid Lièvre, Jean‐Baptiste Bachet et al. Journal of Clinical Oncology profile →
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

2015 503 citations Lise Boussemart, Christine Mateus et al. JAMA Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gorana Tomasic France	33	4.4k	1.7k	1.4k	1.3k	1.3k	63	6.0k
Silvio Veronese Italy	31	3.6k 0.8×	1.6k 0.9×	2.0k 1.4×	1.5k 1.1×	1.1k 0.9×	91	5.4k
Rafael G. Amado United States	21	5.0k 1.1×	1.2k 0.7×	2.3k 1.7×	1.5k 1.1×	1.1k 0.8×	57	6.7k
Élena Elez Spain	38	4.5k 1.0×	1.7k 1.0×	1.4k 1.0×	1.6k 1.2×	1.2k 1.0×	212	6.1k
Allen Lee Cohn United States	38	4.7k 1.1×	1.5k 0.9×	2.4k 1.7×	1.0k 0.8×	1.3k 1.0×	159	6.9k
Milo Frattini Italy	37	4.9k 1.1×	2.6k 1.6×	2.5k 1.8×	2.3k 1.8×	1.9k 1.5×	109	7.6k
Charlotte K.Y. Ng Switzerland	42	2.6k 0.6×	2.4k 1.4×	1.5k 1.1×	1.4k 1.0×	3.5k 2.7×	120	6.5k
J. Randolph Hecht United States	32	7.1k 1.6×	2.5k 1.5×	2.7k 1.9×	1.3k 0.9×	2.5k 1.9×	121	9.2k
Eric A. Collisson United States	30	2.9k 0.7×	2.2k 1.3×	1.0k 0.7×	662 0.5×	2.1k 1.6×	81	5.2k
Rona Yaeger United States	38	4.0k 0.9×	2.5k 1.5×	1.4k 1.0×	2.0k 1.5×	1.6k 1.2×	201	6.1k
Michael J. Pishvaian United States	40	3.8k 0.9×	1.9k 1.2×	1.1k 0.8×	614 0.5×	1.5k 1.2×	216	5.8k

Countries citing papers authored by Gorana Tomasic

Since Specialization

Citations

This map shows the geographic impact of Gorana Tomasic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gorana Tomasic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gorana Tomasic more than expected).

Fields of papers citing papers by Gorana Tomasic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gorana Tomasic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gorana Tomasic. The network helps show where Gorana Tomasic may publish in the future.

Co-authorship network of co-authors of Gorana Tomasic

This figure shows the co-authorship network connecting the top 25 collaborators of Gorana Tomasic. A scholar is included among the top collaborators of Gorana Tomasic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gorana Tomasic. Gorana Tomasic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Evrard, Diane, Émilie Routier, Christine Mateus, et al.. (2018). Sentinel lymph node biopsy in cutaneous head and neck melanoma. European Archives of Oto-Rhino-Laryngology. 275(5). 1271–1279. 10 indexed citations

Adam, Julien, Gorana Tomasic, & Caroline Robert. (2017). Biomarqueurs tissulaires des immunothérapies anti-PD-1 dans le mélanome. Annales de Pathologie. 37(1). 55–60.

Boussemart, Lise, Isabelle Girault, Hélène Malka-Mahieu, et al.. (2016). Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization. Cancer Research. 76(6). 1476–1484. 33 indexed citations

Holderfield, Matthew, Edward Lorenzana, Ben Weisburd, et al.. (2014). Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research. 74(8). 2238–2245. 20 indexed citations

Boussemart, Lise, Joël Claveau, Yungan Tao, et al.. (2013). Vemurafenib and Radiosensitization. JAMA Dermatology. 149(7). 855–855. 71 indexed citations

Perkins, Géraldine, Astrid Lièvre, Tchao Méatchi, et al.. (2010). Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti‐EGFR antibodies in colorectal cancer. International Journal of Cancer. 127(6). 1321–1331. 43 indexed citations

Lièvre, Astrid, Jean‐Baptiste Bachet, Valérie Boige, et al.. (2008). KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Journal of Clinical Oncology. 26(3). 374–379. 1141 indexed citations breakdown →

Goèré, Diane, C. Daveau, D. Élias, et al.. (2008). The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. European Journal of Surgical Oncology. 34(12). 1335–1339. 56 indexed citations

Lièvre, Astrid, Jean‐Baptiste Bachet, Marc Ychou, et al.. (2007). KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab.. Cancer Research. 67. 5671–5671. 7 indexed citations

10.

Conforti, Rosa, Thomas Boulet, Gorana Tomasic, et al.. (2007). Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Annals of Oncology. 18(9). 1477–1483. 69 indexed citations

11.

Élias, Dominique, Diane Goèré, Valérie Boige, et al.. (2007). Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin. Annals of Surgical Oncology. 14(11). 3188–3194. 90 indexed citations

12.

Andreola, Salvatore, Ermanno Leo, Filiberto Belli, et al.. (2001). Adenocarcinoma of the Lower Third of the Rectum Surgically Treated With a <10-MM Distal Clearance: Preliminary Results in 35 N0 Patients. Annals of Surgical Oncology. 8(7). 611–615. 46 indexed citations

13.

Coradini, Danila, Patrizia Boracchi, Maria Grazia Daidone, et al.. (2001). Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. British Journal of Cancer. 85(6). 795–797. 21 indexed citations

14.

Daidone, Maria Grazia, Silvia Veneroni, Elvira Benini, et al.. (1999). Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. International Journal of Cancer. 84(6). 580–586. 46 indexed citations

15.

Ménard, Sylvie, Patrizia Casalini, Gorana Tomasic, et al.. (1999). Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Research and Treatment. 55(2). 167–175. 44 indexed citations

16.

Damiani, Stefania, Marie Ludvíková, Gorana Tomasic, et al.. (1999). Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 434(3). 227–234. 43 indexed citations

17.

Andreola, Salvatore, Ermanno Leo, Filiberto Belli, et al.. (1997). Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Diseases of the Colon & Rectum. 40(1). 25–29. 87 indexed citations

18.

Daidone, Maria Grazia, Elvira Benini, Barbara Valentinis, et al.. (1996). p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours. European Journal of Cancer. 32(8). 1388–1393. 9 indexed citations

19.

Soares, Janine, Gorana Tomasic, Vincenzo Eusebi, & E Bucciarelli. (1994). Intralobular growth of myoepithelial cell carcinoma of the breast. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 425(2). 205–10. 22 indexed citations

20.

Falconieri, Giovanni, et al.. (1993). Cervical cytopathology: An evaluation of its accuracy based on cytohistologic comparison. Cancer. 72(10). 3002–3006. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact